LOGIN  |  REGISTER
Compass Therapeutics

Neogen® Advances Food Safety Data Analytics Strategy

February 24, 2023 | Last Trade: US$12.14 0.12 1.00

LANSING, Mich., Feb. 24, 2023 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) has continued to report successes with the advancement of its Neogen® Analytics software program.

The comprehensive Environmental Monitoring Program (EMP) cloud-based software, powered by Corvium, Inc., connects to both the AccuPoint® Advanced NG and ANSR® systems, and helps users implement food safety systems that reduce risk and elevate compliance. Customers that digitalize their food safety programs by using Neogen Analytics benefit from real-time visibility into all environmental-monitoring tests, as well as automated reporting and alerts for corrective actions. Additionally, Neogen Analytics is an open platform that aggregates food safety data and provides testing recommendations to customers based on industry best practices.

The service continues to be well-received by customers within the industry, as companies are able to standardize their environmental monitoring programs, improve efficiencies through audits, and utilize existing food safety data. This gives them the ability to quickly respond to adverse events in food production facilities, saving time and money, while also aligning with the Food and Drug Administration's "Smarter Era of Food Safety" blueprint for the utilization of digital technologies to improve food safety. To further accelerate its food safety data analytics strategy, Neogen acquired the technology platform and assets of Corvium, Inc., the Virginia-based provider of the software supporting Neogen Analytics, on February 10, 2023.

"We have seen the success of the Neogen Analytics platform and have enjoyed working with the team at Corvium throughout the development and launch of this software," said John Adent, Neogen's President and Chief Executive Officer. "We are pleased to bring their expertise in-house as we continue to drive the growth of this invaluable platform and enhance food safety practices around the world."

Corvium, Inc., launched in 2018 with the mission to use data to make the world a safer place to eat. The company's food risk intelligence platform continuously aggregates and analyzes risk and quality data generated during food production and distribution. Their solutions help food producers and processors prevent pathogenic contamination, comply with federal regulations and internal safety and quality programs, reduce food safety risks and costs, and regulate food waste.

About Neogen

Neogen Corporation develops and markets comprehensive solutions dedicated to food and animal safety, operating with the intention to "Every day, protect the people and animals we care about." The Company's Food Safety segment markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases, and sanitation concerns. Neogen's Animal Safety segment is a leader in the development of genomic solutions along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care, and disinfectants, as well as rodent and insect control solutions.

CONTACT: Bill Waelke, Vice President, Investor Relations
                   517.372.9200, This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB